Document Detail

Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.
MedLine Citation:
PMID:  19440565     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Infliximab's efficacy in the induction and maintenance of remission in luminal Crohn's disease has been confirmed by randomized, controlled trials. Less clearly described are long-term outcomes in the clinical practice setting since the establishment of regularly scheduled, every eight-week maintenance infliximab infusions. Existing reports describing clinical practice outcomes are limited by short durations of follow-up or by the use of episodic dosing, or focus on safety data rather than clinical outcomes.
OBJECTIVE: To examine induction and maintenance responses to infliximab in an outpatient inflammatory bowel disease clinic.
METHODS: A retrospective chart review was performed. Clinical outcomes were infliximab induction and maintenance responses, defined as the ability to stop and remain off corticosteroids while not requiring additional therapy for active disease.
RESULTS: One hundred thirty-three patients were identified with records sufficiently detailed to be analyzed. Of these, 117 patients (88%) demonstrated a clinical response to induction; 104 of 117 (89%) were on concomitant immunosuppressive therapy; 80 of 104 on azathioprine/6-mercaptopurine (77%); and 24 of 104 on methotrexate (23%). The mean duration of clinical response was 94 weeks (95% CI 78.8 to 109.2). The proportion of patients who maintained response at 30 weeks was 83.2%, at 54 weeks was 63.6% and at 108 weeks was 44.9%. Adverse events occurred for 15 of 117 patients (12.8%), consisting of nine infusion reactions, four serum sickness-like reactions, one rash and one infection.
CONCLUSION: Patients treated with infliximab therapy for luminal Crohn's disease in our outpatient clinic achieved excellent induction and maintenance of response rates, confirming the real-life efficacy of maintenance infliximab established in clinical trials.
Christopher W Teshima; Adrienne Thompson; LeRose Dhanoa; Levinus A Dieleman; Richard N Fedorak
Related Documents :
11950005 - Open label study to assess infliximab safety and timing of onset of clinical benefit am...
23528655 - A simplified regimen for focal radiofrequency ablation of barrett mucosa using the halo...
24556095 - Carotid angioplasty with stenting versus endarterectomy: 10-year randomized trial in a ...
24820895 - A modified stapling technique for the repair of an aneurysmal autogenous arteriovenous ...
24150435 - Cost-effectiveness of total disc replacement vs. multidisciplinary rehabilitation in pa...
11723315 - Clinical presentation, natural history, and cumulative death rates of 230 adults with p...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Canadian journal of gastroenterology = Journal canadien de gastroenterologie     Volume:  23     ISSN:  0835-7900     ISO Abbreviation:  Can. J. Gastroenterol.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-14     Completed Date:  2009-07-09     Revised Date:  2014-01-17    
Medline Journal Info:
Nlm Unique ID:  8807867     Medline TA:  Can J Gastroenterol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  348-52     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / administration & dosage,  therapeutic use*
Antibodies, Monoclonal / administration & dosage,  therapeutic use*
Crohn Disease / diagnosis,  drug therapy*
Dose-Response Relationship, Drug
Drug Therapy, Combination
Follow-Up Studies
Immunosuppressive Agents / administration & dosage,  therapeutic use
Infusions, Intravenous
Middle Aged
Remission Induction / methods
Retrospective Studies
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Psoriasis: from gene to clinic.
Next Document:  Clinicopathological features associated with lymph node metastasis in early gastric cancer: analysis...